Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide

An independent FDA advisory panel is set to vote Tuesday on Lynparza's use as a maintenance therapy in BRCA-mutated pancreatic cancer. FDA staffers have raised several questions and concerns, including failure to show a benefit at extending patients' lives and a small trial size, that could undermine the PARP inhibitor's case.